

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT														
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT														
<b>CONVEYING PARTY DATA</b>															
<table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th style="width:70%;">Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Dr. Sebastian Barradeau</td> <td>09/30/2004</td> </tr> <tr> <td>Dr. Eckart Bartnik</td> <td>09/27/2004</td> </tr> <tr> <td>Dr. Joerg Czech</td> <td>09/23/2004</td> </tr> <tr> <td>Dr. Andreas R. Klatt</td> <td>10/03/2004</td> </tr> <tr> <td>Dr. Ekkehard Leberer</td> <td>09/27/2004</td> </tr> <tr> <td>Dr. Thomas Leeuw</td> <td>09/27/2004</td> </tr> </tbody> </table>		Name	Execution Date	Dr. Sebastian Barradeau	09/30/2004	Dr. Eckart Bartnik	09/27/2004	Dr. Joerg Czech	09/23/2004	Dr. Andreas R. Klatt	10/03/2004	Dr. Ekkehard Leberer	09/27/2004	Dr. Thomas Leeuw	09/27/2004
Name	Execution Date														
Dr. Sebastian Barradeau	09/30/2004														
Dr. Eckart Bartnik	09/27/2004														
Dr. Joerg Czech	09/23/2004														
Dr. Andreas R. Klatt	10/03/2004														
Dr. Ekkehard Leberer	09/27/2004														
Dr. Thomas Leeuw	09/27/2004														
<b>RECEIVING PARTY DATA</b>															
<b>Name:</b>	Aventis Pharma Deutschland GmbH														
<b>Street Address:</b>	Bruningstrasse 50														
<b>City:</b>	Frankfurt am Main														
<b>State/Country:</b>	GERMANY														
<b>Postal Code:</b>	D-65929														
<b>PROPERTY NUMBERS Total: 1</b>															
<table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th style="width:30%;">Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>10893025</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	10893025										
Property Type	Number														
Application Number:	10893025														
<b>CORRESPONDENCE DATA</b>															
<b>Fax Number:</b>	(908)231-2626														
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>															
<b>Phone:</b>	908-231-3444														
<b>Email:</b>	robin.inman@aventis.com														
<b>Correspondent Name:</b>	James W. Bolcsak														
<b>Address Line 1:</b>	Route #202-206/P.O. Box 6800														
<b>Address Line 2:</b>	Mail Code: D303-A														
<b>Address Line 4:</b>	Bridgewater, NEW JERSEY 08807														
<b>NAME OF SUBMITTER:</b>	Robin J. Inman														

**CH \$40.00 10893025**

Total Attachments: 4

source=DEAV20030055 US NP - Assignment#page1.tif

source=DEAV20030055 US NP - Assignment#page2.tif

source=DEAV20030055 US NP - Assignment#page3.tif

source=DEAV20030055 US NP - Assignment#page4.tif



ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Sebastian Barradeau, Vorhoelzener Strasse 3, 81477 München, Germany
- 2) Dr. Eckart Bartnik, Karlsruher Straße 8, 65205 Wiesbaden, Germany
- 3) Dr. Joerg Czech, Kreuzacker 2a, 35041 Marburg, Germany
- 4) Dr. Andreas R. Klatt, Sandweg 63, 50827 Köln, , Germany
- 5) Prof. Dr. Ekkehard Leberer, Fichtenstr. 82B, 82110 Germering, Germany
- 6) Dr. Thomas Leeuw, Alpspitzstrasse 11, 86926 Greifenberg, Germany

The inventors are citizens of: 1) FRANCE; 2 - 6) GERMANY ;

hereby sell, assign, and transfer unto **AVENTIS PHARMA DEUTSCHLAND GMBH** ,  
a corporation organized under the laws of **GERMANY** ,  
located at **D-65929 Frankfurt am Main, GERMANY** ,

the entire right, title and interest in and to my/our application for Letters Patent of  
the United States , executed concurrently herewith

Ser.-No.: **10/893,025**

filed: **July 16, 2004**

entitled: **Use of a PAK inhibitor for the Treatment of a Joint Disease**

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said  
application for Letters Patent, and in and to all divisional or continuation applications that  
may be filed for United States Letters Patent for any of said inventions, and in and to all  
patents that may be granted on the foregoing applications, and I/we hereby agree, whenever  
requested, to communicate to said assignee, its successors and assigns, any facts known to  
me/us respecting said inventions, to testify in any legal proceeding, and to execute all  
applications or papers necessary to obtain and maintain proper patent protection on said  
inventions in the United States.

**Inventor(s):**

1<sup>st</sup>: \_\_\_\_\_ Date: \_\_\_\_\_

2<sup>nd</sup>: *Eckart Bartnik* Date: *27.9.04*

3<sup>rd</sup>: *J. Czech* Date: *23.9.04*

4<sup>th</sup>: \_\_\_\_\_ Date: \_\_\_\_\_

5<sup>th</sup>: *Sebastian Barradeau* Date: *27.9.04*

**ASSIGNMENT**

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Sebastian Barradeau, Appartement 2A, 145 rue Pelleport, 75020 Paris, Germany
- 2) Dr. Eckart Bartnik, Karlsruher Straße 8, 65205 Wiesbaden, Germany
- 3) Dr. Joerg Czech, Kreuzacker 2a, 35041 Marburg, Germany
- 4) Dr. Andreas R. Klatt, Sandweg 63, 50827 Köln, , Germany
- 5) Prof. Dr. Ekkehard Leberer, Fichtenstr. 82B, 82110 Germering, Germany
- 6) Dr. Thomas Leeuw, Alpspitzstrasse 11, 86926 Greifenberg, Germany

The inventors are citizens of: 1) FRANCE; 2 - 6) GERMANY ;

hereby sell, assign, and transfer unto **AVENTIS PHARMA DEUTSCHLAND GMBH** ,  
a corporation organized under the laws of **GERMANY** ,  
located at **D-65929 Frankfurt am Main, GERMANY** ,

the entire right, title and interest in and to my/our application for Letters Patent of  
the United States , executed concurrently herewith

Ser.-No.: **10/893,025**

filed: **July 16, 2004**

entitled: **Use of a PAK inhibitor for the Treatment of a Joint Disease**

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said  
application for Letters Patent, and in and to all divisional or continuation applications that  
may be filed for United States Letters Patent for any of said inventions, and in and to all  
patents that may be granted on the foregoing applications, and I/we hereby agree, whenever  
requested, to communicate to said assignee, its successors and assigns, any facts known to  
me/us respecting said inventions, to testify in any legal proceeding, and to execute all  
applications or papers necessary to obtain and maintain proper patent protection on said  
inventions in the United States.

**Inventor(s):**

1<sup>st</sup>: \_\_\_\_\_ Date: \_\_\_\_\_

2<sup>nd</sup>: \_\_\_\_\_ Date: \_\_\_\_\_

3<sup>rd</sup>: \_\_\_\_\_ Date: \_\_\_\_\_

4<sup>th</sup>: Andreas Klatt Date: 03.10.04

5<sup>th</sup>: \_\_\_\_\_ Date: \_\_\_\_\_

6<sup>th</sup>: Shu Li

Date: 2/9/2004